About ProMetic Life Sciences (TSE:PLI)
ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. It operates through three segments: Small-Molecule Therapeutics, Plasma-Derived Therapeutics, and Bioseparation Technologies. The company offers its technology platform for purification of biologics, drug development, proteomics, and elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, inflammation, autoimmune diseases, oncology, and nephropathies. The Small-Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, chronic kidney diseases/diabetic kidney diseases, and metabolic syndrome and its resulting type 2 diabetes, cystic fibrosis related diabetes and liver steatosis, and Alström syndrome. The Plasma-Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. The Bioseparation Technologies segment develops and commercializes affinity chromatography products related to the bioseparation, pathogen reduction, and protein purification. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-48.83%
Return on Assets-26.09%
ProMetic Life Sciences (TSE:PLI) Frequently Asked Questions
What is ProMetic Life Sciences' stock symbol?
ProMetic Life Sciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLI."
How were ProMetic Life Sciences' earnings last quarter?
ProMetic Life Sciences Inc. (TSE:PLI) posted its quarterly earnings results on Tuesday, May, 15th. The company reported ($0.04) earnings per share for the quarter. The business had revenue of $4.29 million for the quarter. ProMetic Life Sciences had a negative return on equity of 48.83% and a negative net margin of 73.85%. View ProMetic Life Sciences' Earnings History.
When is ProMetic Life Sciences' next earnings date?
What price target have analysts set for PLI?
6 brokers have issued 1-year target prices for ProMetic Life Sciences' stock. Their predictions range from C$0.60 to C$4.00. On average, they expect ProMetic Life Sciences' share price to reach C$1.89 in the next year. View Analyst Ratings for ProMetic Life Sciences.
Who are some of ProMetic Life Sciences' key competitors?
Some companies that are related to ProMetic Life Sciences include ABLYNX NV/ADR (ABLX), MorphoSys (MPSYY), BTG (BTG), Abcam (ABC), MorphoSys (MOR), Sosei Group (SOLTF), Sirtex Medical (SRX), Genus (GNS), Biotest (BIO), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH) and Starpharma (SPL).
Who are ProMetic Life Sciences' key executives?
ProMetic Life Sciences' management team includes the folowing people:
- Mr. Pierre Laurin, Pres, CEO & Non-Independent Director (Age 57)
- Mr. Bruce Pritchard, COO & Interim CFO
- Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
- Mr. Bruce Wendel, Chief Bus. Devel. Officer & Director (Age 64)
- Dr. John Moran, Chief Medical Officer (Age 72)
Has ProMetic Life Sciences been receiving favorable news coverage?
News headlines about PLI stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ProMetic Life Sciences earned a news impact score of 0.15 on Accern's scale. They also gave news articles about the company an impact score of 46.46 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of ProMetic Life Sciences?
Shares of PLI and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is ProMetic Life Sciences' stock price today?
One share of PLI stock can currently be purchased for approximately C$0.63.
How big of a company is ProMetic Life Sciences?
ProMetic Life Sciences has a market capitalization of C$1.04 billion.
How can I contact ProMetic Life Sciences?
ProMetic Life Sciences' mailing address is 440 Armand-Frappier Blvd Suite 300, LAVAL, QC H7V 4B4, Canada. The company can be reached via phone at +1-450-7810115.
MarketBeat Community Rating for ProMetic Life Sciences (PLI)MarketBeat's community ratings are surveys of what our community members think about ProMetic Life Sciences and other stocks. Vote "Outperform" if you believe PLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLI will underperform the S&P 500 over the long term. You may vote once every thirty days.